COCHLEAR LIMITED (COH)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:
COH - COCHLEAR LIMITED
FNArena Sector :
Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.4
Index: ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS
FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.4
Cochlear is a medical device company that designs, manufactures and supplies hearing implants to the global market. Formed in 1981 with finance from the Australian government, it became a listed entity in 1995, and has grown to become the global leader in its field.
LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
---|---|---|---|
$290.51
12 Dec |
-2.930 OPEN $292.83 |
-1.00% HIGH $294.78 |
126,437 LOW $288.65 |
TARGET | |||||
|
|||||
Franking for last dividend paid out: 80% |
OTHER COMPANIES IN THE SAME SECTOR | |||
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . CSX . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IDX . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI . VTI . |
FNARENA'S MARKET CONSENSUS FORECASTS
Title | FY23 Actual |
FY24 Actual |
FY25 Forecast |
FY26 Forecast |
---|---|---|---|---|
EPS (cps) | xxx | 544.4 | 636.5 | xxx |
DPS (cps) | xxx | 410.0 | 448.5 | xxx |
EPS Growth | xxx | 19.1% | 16.9% | xxx |
DPS Growth | xxx | 24.2% | 9.4% | xxx |
PE Ratio | xxx | N/A | 45.8 | xxx |
Dividend Yield | xxx | N/A | 1.5% | xxx |
Div Pay Ratio(%) | xxx | 75.3% | 70.5% | xxx |
Last ex-div: 17/09 - ex-div 210c (franking 80%)
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|
EPS Basic | xxx | xxx | xxx | xxx | xxx | 544.4 |
DPS All | xxx | xxx | xxx | xxx | xxx | 410.0 |
Sales/Revenue | xxx | xxx | xxx | xxx | xxx | 2,258.2 M |
Book Value Per Share | xxx | xxx | xxx | xxx | xxx | 2,817.3 |
Net Operating Cash Flow | xxx | xxx | xxx | xxx | xxx | 388.8 M |
Net Profit Margin | xxx | xxx | xxx | xxx | xxx | 15.80 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
Title | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|
Return on Capital Employed | xxx | xxx | xxx | xxx | xxx | 19.88 % |
Return on Invested Capital | xxx | xxx | xxx | xxx | xxx | 18.05 % |
Return on Assets | xxx | xxx | xxx | xxx | xxx | 13.43 % |
Return on Equity | xxx | xxx | xxx | xxx | xxx | 19.88 % |
Return on Total Capital | xxx | xxx | xxx | xxx | xxx | 25.85 % |
Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | xxx | 80.7 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
Title | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|
Short-Term Debt | xxx | xxx | xxx | xxx | xxx | 42 M |
Long Term Debt | xxx | xxx | xxx | xxx | xxx | 202 M |
Total Debt | xxx | xxx | xxx | xxx | xxx | 244 M |
Goodwill - Gross | xxx | xxx | xxx | xxx | xxx | 258 M |
Cash & Equivalents - Generic | xxx | xxx | xxx | xxx | xxx | 514 M |
Price To Book Value | xxx | xxx | xxx | xxx | xxx | 11.79 |
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
Cash & Equivalents - Generic
Price To Book Value
Title | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|
Capex | xxx | xxx | xxx | xxx | xxx | 89.8 M |
Capex % of Sales | xxx | xxx | xxx | xxx | xxx | 3.98 % |
Cost of Goods Sold | xxx | xxx | xxx | xxx | xxx | 562 M |
Selling, General & Admin. Exp & Other | xxx | xxx | xxx | xxx | xxx | 1,175 M |
Research & Development | xxx | xxx | xxx | xxx | xxx | 277 M |
Investments - Total | xxx | xxx | xxx | xxx | xxx | 185 M |
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
EXTRA COVERAGE
Display All Commentary
No. Of Recommendations
Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.
COH STOCK CHART
FNArena News on COH
1 |
Rudi’s View: Best Buys & Smaller Cap FavouritesDec 12 2024 - Rudi's View |
2 |
Rudi’s View: In Santa We Trust (?)Dec 05 2024 - Rudi's View |
3 |
Rudi’s View: Trump Beneficiaries & TechOneNov 28 2024 - Rudi's View |
4 |
Rudi’s View: The Importance Of ‘Quality’ GrowthNov 21 2024 - Rudi's View |
5 |
Rudi’s View: A Rally With No Earnings SupportNov 14 2024 - Rudi's View |
Latest Medical Equipment & Devices News
1 |
ResMed’s Bounce-Back CompleteOct 29 2024 - Australia |
2 |
Dr Boreham’s Crucible: Pro MedicusSep 04 2024 - Australia |
3 |
Pro Medicus: Don’t Stop Me NowAug 20 2024 - Technicals |
4 |
Dr Boreham’s Crucible: BlinklabMay 20 2024 - Small Caps |
5 |
ResMed Silences The DoubtersApr 29 2024 - Australia |
6 |
Dr Boreham’s Crucible: 4D MedicalApr 23 2024 - Small Caps |
7 |
Uptrend Resumed For ResMedMar 19 2024 - Technicals |
8 |
Dr Boreham’s Crucible: CochlearFeb 28 2024 - Australia |
9 |
Rudi Interviewed: Ongoing Potential In Technology & GrowthFeb 19 2024 - Rudi's View |
10 |
Dr Boreham’s Crucible: ArtryaFeb 15 2024 - Small Caps |